Cargando…

Merits of Level III Axillary Dissection in Node-Positive Breast Cancer: A Prospective, Single-Institution Study From India

PURPOSE: A complete axillary lymph node (ALN) dissection is therapeutic in node-positive breast cancer. Presently, there is no international consensus regarding anatomic levels to be addressed in complete axillary dissection. We assessed the burden of disease in level III axilla. MATERIALS AND METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Shalaka, Noronha, Jarin, Hawaldar, Rohini, Kundgulwar, Girish, Vanmali, Vaibhav, Parmar, Vani, Nair, Nita, Shet, Tanuja, Badwe, Rajendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426546/
https://www.ncbi.nlm.nih.gov/pubmed/30811304
http://dx.doi.org/10.1200/JGO.18.00165
_version_ 1783405026387951616
author Joshi, Shalaka
Noronha, Jarin
Hawaldar, Rohini
Kundgulwar, Girish
Vanmali, Vaibhav
Parmar, Vani
Nair, Nita
Shet, Tanuja
Badwe, Rajendra
author_facet Joshi, Shalaka
Noronha, Jarin
Hawaldar, Rohini
Kundgulwar, Girish
Vanmali, Vaibhav
Parmar, Vani
Nair, Nita
Shet, Tanuja
Badwe, Rajendra
author_sort Joshi, Shalaka
collection PubMed
description PURPOSE: A complete axillary lymph node (ALN) dissection is therapeutic in node-positive breast cancer. Presently, there is no international consensus regarding anatomic levels to be addressed in complete axillary dissection. We assessed the burden of disease in level III axilla. MATERIALS AND METHODS: A prospectively maintained database was assessed for 1,591 consecutive patients with nonmetastatic breast cancer registered at Tata Memorial Center, Mumbai, between January 2009 and December 2014. RESULTS: A median of four (zero to 20) level III ALNs were dissected and a median of two (one to 17) nodes were positive. A total of 27.3% (434 of 1,591) patients had level III ALN metastasis, and 4.7% of patients had positive interpectoral nodes. Some 53.2% of patients had level III metastases in the presence of four or more positive level I and II ALNs. A total of 9.4% of patients had level III involvement when one to three ALNs were positive in level I and II (P < .001). Some 53.2% of patients had level III metastases in the presence of four or more positive level I and II ALNs. On logistic regression analysis, four or more positive ALNs in level I or II (P < .001), inner/central quadrant tumor location (P = .013), and perinodal extension (P < .001) were associated with level III ALN involvement. At a median follow-up of 36 months, the disease-free survival was significantly worse for level III ALN metastases on univariate analysis (P < .001). On multivariate Cox regression analysis, histologic grade (P = .006), four or more positive ALNs (P < .001), hormone receptor status (P < .001), and tumor size (P = .037) were independent prognostic factors for disease-free survival. CONCLUSION: The axillary nodal burden is high in patients with breast cancer in developing countries like India. One of two women with four or more positive level I and II ALNs may have residual disease in level III if it is not cleared during surgery. Intraoperative interpectoral space clearance should be considered in the presence of either palpable interpectoral lymph nodes or multiple positive ALNs.
format Online
Article
Text
id pubmed-6426546
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-64265462019-04-09 Merits of Level III Axillary Dissection in Node-Positive Breast Cancer: A Prospective, Single-Institution Study From India Joshi, Shalaka Noronha, Jarin Hawaldar, Rohini Kundgulwar, Girish Vanmali, Vaibhav Parmar, Vani Nair, Nita Shet, Tanuja Badwe, Rajendra J Glob Oncol Original Report PURPOSE: A complete axillary lymph node (ALN) dissection is therapeutic in node-positive breast cancer. Presently, there is no international consensus regarding anatomic levels to be addressed in complete axillary dissection. We assessed the burden of disease in level III axilla. MATERIALS AND METHODS: A prospectively maintained database was assessed for 1,591 consecutive patients with nonmetastatic breast cancer registered at Tata Memorial Center, Mumbai, between January 2009 and December 2014. RESULTS: A median of four (zero to 20) level III ALNs were dissected and a median of two (one to 17) nodes were positive. A total of 27.3% (434 of 1,591) patients had level III ALN metastasis, and 4.7% of patients had positive interpectoral nodes. Some 53.2% of patients had level III metastases in the presence of four or more positive level I and II ALNs. A total of 9.4% of patients had level III involvement when one to three ALNs were positive in level I and II (P < .001). Some 53.2% of patients had level III metastases in the presence of four or more positive level I and II ALNs. On logistic regression analysis, four or more positive ALNs in level I or II (P < .001), inner/central quadrant tumor location (P = .013), and perinodal extension (P < .001) were associated with level III ALN involvement. At a median follow-up of 36 months, the disease-free survival was significantly worse for level III ALN metastases on univariate analysis (P < .001). On multivariate Cox regression analysis, histologic grade (P = .006), four or more positive ALNs (P < .001), hormone receptor status (P < .001), and tumor size (P = .037) were independent prognostic factors for disease-free survival. CONCLUSION: The axillary nodal burden is high in patients with breast cancer in developing countries like India. One of two women with four or more positive level I and II ALNs may have residual disease in level III if it is not cleared during surgery. Intraoperative interpectoral space clearance should be considered in the presence of either palpable interpectoral lymph nodes or multiple positive ALNs. American Society of Clinical Oncology 2019-02-27 /pmc/articles/PMC6426546/ /pubmed/30811304 http://dx.doi.org/10.1200/JGO.18.00165 Text en © 2019 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/
spellingShingle Original Report
Joshi, Shalaka
Noronha, Jarin
Hawaldar, Rohini
Kundgulwar, Girish
Vanmali, Vaibhav
Parmar, Vani
Nair, Nita
Shet, Tanuja
Badwe, Rajendra
Merits of Level III Axillary Dissection in Node-Positive Breast Cancer: A Prospective, Single-Institution Study From India
title Merits of Level III Axillary Dissection in Node-Positive Breast Cancer: A Prospective, Single-Institution Study From India
title_full Merits of Level III Axillary Dissection in Node-Positive Breast Cancer: A Prospective, Single-Institution Study From India
title_fullStr Merits of Level III Axillary Dissection in Node-Positive Breast Cancer: A Prospective, Single-Institution Study From India
title_full_unstemmed Merits of Level III Axillary Dissection in Node-Positive Breast Cancer: A Prospective, Single-Institution Study From India
title_short Merits of Level III Axillary Dissection in Node-Positive Breast Cancer: A Prospective, Single-Institution Study From India
title_sort merits of level iii axillary dissection in node-positive breast cancer: a prospective, single-institution study from india
topic Original Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426546/
https://www.ncbi.nlm.nih.gov/pubmed/30811304
http://dx.doi.org/10.1200/JGO.18.00165
work_keys_str_mv AT joshishalaka meritsofleveliiiaxillarydissectioninnodepositivebreastcanceraprospectivesingleinstitutionstudyfromindia
AT noronhajarin meritsofleveliiiaxillarydissectioninnodepositivebreastcanceraprospectivesingleinstitutionstudyfromindia
AT hawaldarrohini meritsofleveliiiaxillarydissectioninnodepositivebreastcanceraprospectivesingleinstitutionstudyfromindia
AT kundgulwargirish meritsofleveliiiaxillarydissectioninnodepositivebreastcanceraprospectivesingleinstitutionstudyfromindia
AT vanmalivaibhav meritsofleveliiiaxillarydissectioninnodepositivebreastcanceraprospectivesingleinstitutionstudyfromindia
AT parmarvani meritsofleveliiiaxillarydissectioninnodepositivebreastcanceraprospectivesingleinstitutionstudyfromindia
AT nairnita meritsofleveliiiaxillarydissectioninnodepositivebreastcanceraprospectivesingleinstitutionstudyfromindia
AT shettanuja meritsofleveliiiaxillarydissectioninnodepositivebreastcanceraprospectivesingleinstitutionstudyfromindia
AT badwerajendra meritsofleveliiiaxillarydissectioninnodepositivebreastcanceraprospectivesingleinstitutionstudyfromindia